Huyết áp và xơ vữa động mạch: Những hệ quả lâm sàng từ thử nghiệm ALLHAT

U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003. Committee on Quality of Health Care in America, Institute of Medicine: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington DC: National Academy Press; 2001. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252. U.S. Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health, edn 2. Washington, DC: U.S. Government Printing Office; 2000. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997. Elliott WJ: ALLHAT: the largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial. Am J Hypertens 1996, 9:409–411. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE: Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22–27. Vallet B: Endothelial cell dysfunction and abnormal tissue perfusion. Crit Care Med 2002, 30(5 Suppl):S229-S234. Taylor AA: Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2001, 30:983–997. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844–2850. Standridge JB: A family physician questions the conclusions from ALLHAT. Am J Hypertens 2004, 17:361–365. Laragh JH, Sealey JE: Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003, 16:407–415. Mazzerli FH: ALLHAT, or the soft science of the secondary end point. Ann Intern Med 2003, 139:777–780. Gradman AH: Managing high-risk patients with hypertension: focus on the renin-angiotensin system. J Clin Hypertens 2004, 6:501–508. Hansson L, Zanchetti A, Carruthers, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755–1762. Wing LM, Reid CM, Ryan P, et al., for the Second Australian National Blood Pressure Study Group: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583–592. Resnick LM: Why we can’t translate clinical trials into clinical practice in hypertension. Am J Hypertens 2003, 16:421–425. Neutel JM: Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004, 18:599–606. Huang XR, Chen WY, Truong LD, Lan HY: Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003, 14:1738–1747. Resnick LM, Catanzaro D, Sealey JE, Laragh JH: Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system. Am J Hypertension 2004, 17:203–208. Kang DH, Yu ES, Park JE, et al.: Uric acid induced C-reactive protein (CRP) expression via upregulation of angiotensin type 1 receptors (AT1) in vascular endothelial cells and smooth muscle cells [abstract]. J Am Soc Nephrol 2003, 14:136A. Kanellis J, Watanabe S, Li JH, et al.: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003, 41:1287–1293. Savage PJ, Pressel SL, Curb JD, et al.: Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998, 158:741–751. de Leeuw PW: Renal function in the elderly: results from the European Working Party on High Blood Pressure in the Elderly trial. Am J Med 1991, 90:45S-49S. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153. Verdecchia P, Reboldi G, Angeli F, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963–969. Griffin KA, Bidani AK: Calcium-channel blockers and the progression of renal disease. Curr Hypertens Rep 1999, 1:436–445. Griffin KA, Picken MM, Bidani AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995, 96:793–800. Komatsu K, Numabe A, Ono Y, Frohlich ED: Hydrochloro-thiazide increases efferent glomerular arteriolar resistance in spontaneously hypertensive rats. J Cardiovasc Pharmacol Ther 1996, 1:57–64. Ono Y, Ono H, Frohlich ED: Hydrochlorothiazide exacerbates nitric oxide-blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996, 14:823–828. Coresh J, Wei GL, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States. Arch Intern Med 2001, 16:207–216. Psaty BM, Lumley T, Furberg CD, et al.: Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003, 289:2534–2544. Selby JV, Friedman GD, Quesenberry CP Jr: Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990, 131:1017–1027. Hunt SC, Stephenson SH, Hopkins PN, Williams RR: Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 1991, 17:969–976. Jossa F, Farinaro E, Panico S, et al.: Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994, 8:677–681. Taniguchi Y, Hayashi T, Tsumura K, et al.: Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men. The Osaka Health Survey. J Hypertens 2001, 19:1209–1215. Masuo K, Kawaguchi H, Mikami H, et al.: Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003, 42:474–480. Nakanishi N, Okamato M, Yoshida H, et al.: Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003, 18:523–530. Cannon PJ, Stason WB, Demartini FE, et al.: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966, 275:457–464. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253–259. Ruggenenti P, Perna A, Gherardi G, et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359–364. Dahlof B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:995–1003. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes: a blood pressure-independent effect. Circulation 2002, 106:672–678. Wright JT Jr, Bakris G, Greene T, et al.; African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421–2431. Jamerson KA, Bakris GL, Wun CC, et al.: Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcomes effects of first-line combination therapies in hypertension. Am J Hypertens 2004, 17:793–801.